Captopril and losartan modify mitogen-induced proliferative response and expression of some differentiation antigents on peripheral blood mononuclear cells in chronic uraemic patients

Archives of Medical Science

Volumn 5, Issue 3, 2009, Pages 401-407

  Bartnicki, Piotr ^a   Majewska, Ewa ^b   Wilk, Radosław ^a   Baj, Zbigniew ^b   Rysz, Jacek ^a  

^a Department of Nephrology Hypertension and Family Medicine ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Blood mononuclear cells; Captopril; Chronic uraemia; Differentiation antigens; Losaratan; Proliferative response

Indexed keywords

CAPTOPRIL; DIFFERENTIATION ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; MITOGENIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ P;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; UREMIA;

EID: 73449098920     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ehlers M, Riordan J. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 1989; 28: 5311-8.
2. Gomez RA, Norling LL, Wilfong N, Isakson P, Lynch KR, Hock R, Quesenberry P. Leukocytes synthesise angiotensinogen. Hypertension 1993; 21: 470-5.
3. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 1995; 91: 1129-34.
4. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol 1998; 160: 1436-43.
5. Thomas DW, Hoffman MD. Identification of macrophage receptor for angiotensin: a potential role in antigen uptake for T lymphocyte responses? J Immunol 1984; 132: 2807-12.
6. Suzuki H, Shibata H, Murakami M, et al. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leukocytes. J Endocr 1995; 42: 15-22.
7. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583-96.
8. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990; 22: 739-47.
9. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacol 1997; 36: 49-55.
10. Schihdler R, Dinarello CA, Koch KM. Angiotensin-converting enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995; 7: 526-33.
11. Geiger H, Fierlbeck W, Mai M, et al. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 1997; 51: 750-61.
12. Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178-80.
13. Shasha SM, Nusam D, Labin L, et al. Effect of converting enzyme inhibitor captopril on T cell functions in essential hypertension. Nephron 1991; 59: 586-90.
14. Delfraissy JF, Galanaud P, Balavoine JF, Wallon C, Dormont J. Captopril and immune regulation. Kidney Int 1984; 25: 925-9.
15. Odaka C, Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation - induced apoptosis by interfering with T cell activation signals. Clin Exp Immunol 2000; 121: 515-22.
16. Martin MF, McKenna F, Bird HA, Surrall KE, Dixon JS, Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet 1984; 1: 1325-7.
17. Herlitz H, Edeno C, Mulec H, Westberg G, Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron 1984; 38: 253-6.
18. Raiden S, Giordano M, Andonegui G, et al. Losartan, a selective inhibitor of subtype ATI receptors for angiotensin II, inhibits the binding of N-formylmethionylleucyl-phenylalanine to neutrophil receptors. J Pharmacol Exp Therap 1997; 281: 624-8.
19. Raiden S, Pereyra Y, Nahmod V, et al. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP. J Leukoc Biol 2000; 65: 700-6.
20. Sonmez A, Kisa U, Uckaya G, et al. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J Renin Angiotensin Aldosteron Syst 2001; 2: 112-6.
21. Shibasaki Y, Mod Y, Tsutumi Y, et al. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 1999; 51: 83-91.
22. Ferrante H, Thong YH. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the hypaque-ficoll technique. J Immunol Methods 1978; 24: 389-93.
23. Zeman K, Tchórzewski H, Majewska E, Pokoca L, Pinkowski R. A simple and rapid method of simultaneous isolation of highly purified lymphocytes and neutrophilic granulocytes from blood [Polish]. Immunol Pol 1988; 13: 217-24.
24. Sica DA, Lo MW, Shaw WC, et al. The pharmacokinetics of losartan in renal insufficiency J Hypertens 1995; 13: S49-52.
25. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-8.
26. Lal RB, Edison LI, Chused TM. Fixation and long-term storage of human lymphocytes for surface marker analysis for flow cytometry. Cytometry 1988; 9: 213-9.
27. Minakuchi R, Wacholtz MC, Davis LS, Lipsky PE. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol 1990; 145: 2616-25.
28. Johnsen SA, Persson IB, Aurell M. PGE2 production after angiotensin-converting enzyme inhibition. Scand J Urol Nephrol 1997; 31: 81-8.
29. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23: 1745-51.
30. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290: 33-40.
31. Edwards RM, Aiyar N. Angiotensin II receptors subtypes in the kidney. J Am Soc Nephrol 1993; 3: 1643-52.
32. Vance BA, Kelly CJ. A nephritogenic T cell clone expresses components of the rennin-angiotensin system and is responsive to angiotensin II (abstract). J Am Soc Nephrol 1994; 5: 772A.
33. Janeway CA Jr, Medhzhitov R, Pfeiffer C, Tao X, Bottomly K. Altered peptide ligands. Conformational changes in the TcR. Immunologist 1995; 3: 41-7.